HRP20190173T1 - Oralne formulacije deferasiroksa - Google Patents

Oralne formulacije deferasiroksa

Info

Publication number
HRP20190173T1
HRP20190173T1 HRP20190173TT HRP20190173T HRP20190173T1 HR P20190173 T1 HRP20190173 T1 HR P20190173T1 HR P20190173T T HRP20190173T T HR P20190173TT HR P20190173 T HRP20190173 T HR P20190173T HR P20190173 T1 HRP20190173 T1 HR P20190173T1
Authority
HR
Croatia
Prior art keywords
deferasirox
oral formulations
formulations
oral
Prior art date
Application number
HRP20190173TT
Other languages
English (en)
Croatian (hr)
Inventor
Indrajit Ghosh
Jia-Ai Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190173(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20190173T1 publication Critical patent/HRP20190173T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20190173TT 2013-03-08 2014-03-06 Oralne formulacije deferasiroksa HRP20190173T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361774893P 2013-03-08 2013-03-08
US201361824435P 2013-05-17 2013-05-17
EP14710654.6A EP2964202B2 (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox
PCT/IB2014/059494 WO2014136079A1 (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox

Publications (1)

Publication Number Publication Date
HRP20190173T1 true HRP20190173T1 (hr) 2019-03-22

Family

ID=50288212

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190173TT HRP20190173T1 (hr) 2013-03-08 2014-03-06 Oralne formulacije deferasiroksa
HRP20180387TT HRP20180387T1 (hr) 2013-03-08 2018-03-06 Oralne formulacije deferasiroksa

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20180387TT HRP20180387T1 (hr) 2013-03-08 2018-03-06 Oralne formulacije deferasiroksa

Country Status (41)

Country Link
US (4) US9283209B2 (enExample)
EP (2) EP2964202B2 (enExample)
JP (3) JP6434429B2 (enExample)
KR (2) KR101925671B1 (enExample)
CN (1) CN105025886B (enExample)
AP (1) AP2015008668A0 (enExample)
AU (2) AU2014224198B2 (enExample)
BR (1) BR112015021254A2 (enExample)
CA (1) CA2890465A1 (enExample)
CL (1) CL2015002495A1 (enExample)
CR (1) CR20150467A (enExample)
CU (1) CU24348B1 (enExample)
CY (2) CY1120021T1 (enExample)
DK (2) DK3124018T3 (enExample)
DO (1) DOP2015000220A (enExample)
EA (1) EA031719B1 (enExample)
EC (1) ECSP15042897A (enExample)
ES (2) ES2663135T5 (enExample)
HR (2) HRP20190173T1 (enExample)
HU (2) HUE036921T2 (enExample)
IL (1) IL240797B (enExample)
JO (1) JO3570B1 (enExample)
LT (2) LT3124018T (enExample)
ME (1) ME03297B (enExample)
MX (1) MX361055B (enExample)
MY (1) MY170303A (enExample)
NI (1) NI201500126A (enExample)
NZ (1) NZ711179A (enExample)
PE (1) PE20151600A1 (enExample)
PH (1) PH12015501981B1 (enExample)
PL (2) PL2964202T3 (enExample)
PT (2) PT3124018T (enExample)
RS (2) RS58317B1 (enExample)
SA (1) SA515360425B1 (enExample)
SG (2) SG10201807204YA (enExample)
SI (2) SI2964202T1 (enExample)
TN (1) TN2015000393A1 (enExample)
TW (2) TWI686215B (enExample)
UY (1) UY35367A (enExample)
WO (1) WO2014136079A1 (enExample)
ZA (1) ZA201506060B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101925671B1 (ko) 2013-03-08 2019-02-27 노파르티스 아게 데페라시록스의 경구 제제
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
WO2016167729A1 (en) * 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
HK1254608A1 (zh) 2015-06-17 2019-07-26 Dispersol Technologies, Llc 改良的地拉罗司制剂及其制备方法
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2018007956A1 (en) * 2016-07-05 2018-01-11 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
EP3854385A1 (en) * 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
WO2022186809A1 (en) * 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
WO2025242589A1 (en) 2024-05-21 2025-11-27 Chiesi Farmaceutici S.P.A. Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
KR20070022243A (ko) * 2004-04-08 2007-02-26 노파르티스 아게 데페라시록스 분산성 정제
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
CN101291655A (zh) * 2005-10-19 2008-10-22 诺瓦提斯公司 包含地拉罗司(deferasirox)的分散片
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
US20110097413A1 (en) 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
WO2010143006A1 (en) * 2009-06-10 2010-12-16 Carlo Ghisalberti Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease
KR20130041144A (ko) * 2010-07-08 2013-04-24 라티오팜 게엠베하 데페라시록스의 경구투여용 제제
AP3578A (en) 2010-10-01 2016-02-08 Cipla Ltd Pharmaceutical composition comprising deferasirox
KR101925671B1 (ko) 2013-03-08 2019-02-27 노파르티스 아게 데페라시록스의 경구 제제
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox

Also Published As

Publication number Publication date
ES2708955T5 (es) 2023-11-10
AU2017203897B2 (en) 2019-02-14
EP2964202A1 (en) 2016-01-13
DK3124018T3 (en) 2018-03-26
HK1212242A1 (en) 2016-06-10
KR20170045391A (ko) 2017-04-26
JP2020180123A (ja) 2020-11-05
EA201591665A1 (ru) 2015-12-30
DOP2015000220A (es) 2015-11-30
ME03297B (me) 2019-07-20
IL240797B (en) 2022-01-01
PT3124018T (pt) 2018-03-22
MX2015011962A (es) 2016-07-07
HUE041224T2 (hu) 2019-05-28
JP2016510068A (ja) 2016-04-04
CN105025886A (zh) 2015-11-04
SI2964202T1 (sl) 2019-02-28
MY170303A (en) 2019-07-17
EP2964202B1 (en) 2018-10-31
TN2015000393A1 (en) 2017-01-03
IL240797A0 (en) 2015-10-29
PL2964202T3 (pl) 2019-04-30
TW201838623A (zh) 2018-11-01
CY1121315T1 (el) 2020-05-29
US9283209B2 (en) 2016-03-15
ZA201506060B (en) 2016-12-21
AP2015008668A0 (en) 2015-08-31
PH12015501981A1 (en) 2016-01-11
SG11201506491RA (en) 2015-09-29
CU24348B1 (es) 2018-05-08
UY35367A (es) 2014-10-31
ES2663135T3 (es) 2018-04-11
LT2964202T (lt) 2019-02-11
PH12015501981B1 (en) 2016-01-11
CR20150467A (es) 2015-10-27
DK2964202T3 (en) 2019-02-25
RS58317B1 (sr) 2019-03-29
CY1120021T1 (el) 2018-12-12
KR101925671B1 (ko) 2019-02-27
LT3124018T (lt) 2018-03-12
TWI686215B (zh) 2020-03-01
BR112015021254A2 (pt) 2017-07-18
TW201442742A (zh) 2014-11-16
ECSP15042897A (es) 2019-03-29
AU2017203897A1 (en) 2017-06-29
US20160220493A1 (en) 2016-08-04
AU2014224198A1 (en) 2015-09-10
KR20150126900A (ko) 2015-11-13
CU20150110A7 (es) 2016-04-25
WO2014136079A1 (en) 2014-09-12
EA031719B1 (ru) 2019-02-28
JO3570B1 (ar) 2020-07-05
US20150017241A1 (en) 2015-01-15
NZ711179A (en) 2018-07-27
PE20151600A1 (es) 2015-11-26
HUE036921T2 (hu) 2018-08-28
NI201500126A (es) 2015-11-18
PL3124018T3 (pl) 2018-05-30
SI3124018T1 (en) 2018-04-30
EP3124018B2 (en) 2024-04-24
MX361055B (es) 2018-11-26
US20170290811A1 (en) 2017-10-12
EP3124018B1 (en) 2017-12-20
TWI625136B (zh) 2018-06-01
CN105025886B (zh) 2019-01-15
ES2663135T5 (en) 2024-12-16
EP2964202B2 (en) 2023-05-31
CL2015002495A1 (es) 2016-03-04
CA2890465A1 (en) 2014-09-12
ES2708955T3 (es) 2019-04-12
US20180221285A1 (en) 2018-08-09
RS56890B1 (sr) 2018-04-30
SA515360425B1 (ar) 2018-01-21
EP3124018A1 (en) 2017-02-01
PT2964202T (pt) 2019-02-06
SG10201807204YA (en) 2018-09-27
JP2018162255A (ja) 2018-10-18
HRP20180387T1 (hr) 2018-04-20
JP6434429B2 (ja) 2018-12-05
AU2014224198B2 (en) 2017-06-15
JP6739470B2 (ja) 2020-08-12

Similar Documents

Publication Publication Date Title
ME03297B (me) Oralne formulacije deferasiroksa
EP3065716C0 (en) FORMULATIONS
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
PT3030262T (pt) Composição farmacêutica de associação
HRP20180684T1 (hr) Kombinacija lijekova
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
IL245855B (en) Oral formulations of pyrrolidine derivatives
PT2953948T (pt) Antagonistas de integrina fluorada
EP2934533A4 (en) INHIBITORS OF THE RENAL KALIUM CHANNEL OF THE OUTER MEDULLA
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
EP2945942A4 (en) Voriconazole IMMUNOASSAY
EP2968389A4 (en) OPHTHALMIC FORMULATIONS
HRP20181307T1 (hr) Postupak izrade zubne proteze
EP2988734C0 (en) FORMULATION OF A HARD CAPSULE
BR112016002561A2 (pt) implemento de cuidado oral
IL252447B (en) Oral care composition
IL256719B (en) Oral care compositions
IL243447A0 (en) Formulations of methaxelone
EP2986634A4 (en) Cocrystalline dhea formulations
TH1501005166A (th) สูตรที่ให้ทางปากของดีฟีราซิรอกซ์ (deferasirox)
TH1501001055A (th) ชิ้นสอดช่องปาก
CL2015003768A1 (es) Procedimientos y composiciones de formulaciones a grano
ES1098808Y (es) Juguete-instrumento de muneco bailarin
CO6990731A2 (es) Composiciones de cuidado oral